{
    "organizations": [],
    "uuid": "157c6ec5274c4518bccf0f2a138dbb7a0bfd1038",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update-and-host-conference-call.html",
    "ord_in_thread": 0,
    "title": "Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "MENLO PARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).\nConference Call Information\nTo participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.\nA replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.\nAbout Corcept Therapeutics Incorporated\nCorcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym ® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.\nCONTACT:\nCharles Robb\nChief Financial Officer\nCorcept Therapeutics\n650-688-8783\ncrobb@corcept.com\nwww.corcept.com\nSource:Corcept Therapeutics Incorporated",
    "published": "2018-05-02T00:05:00.000+03:00",
    "crawled": "2018-05-02T02:45:12.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "menlo",
        "park",
        "may",
        "globe",
        "newswire",
        "corcept",
        "therapeutic",
        "incorporated",
        "nasdaq",
        "cort",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "may",
        "company",
        "also",
        "host",
        "conference",
        "call",
        "day",
        "eastern",
        "time",
        "pacific",
        "time",
        "conference",
        "call",
        "information",
        "participate",
        "dial",
        "united",
        "state",
        "internationally",
        "approximately",
        "minute",
        "start",
        "call",
        "passcode",
        "replay",
        "available",
        "may",
        "united",
        "state",
        "internationally",
        "passcode",
        "corcept",
        "therapeutic",
        "incorporated",
        "corcept",
        "pharmaceutical",
        "company",
        "engaged",
        "discovery",
        "development",
        "commercialization",
        "drug",
        "treat",
        "severe",
        "metabolic",
        "oncologic",
        "psychiatric",
        "disorder",
        "modulating",
        "effect",
        "cortisol",
        "korlym",
        "company",
        "first",
        "medication",
        "corcept",
        "large",
        "portfolio",
        "proprietary",
        "compound",
        "modulate",
        "effect",
        "cortisol",
        "progesterone",
        "corcept",
        "owns",
        "extensive",
        "united",
        "state",
        "foreign",
        "intellectual",
        "property",
        "covering",
        "use",
        "cortisol",
        "modulators",
        "treatment",
        "wide",
        "variety",
        "serious",
        "disorder",
        "including",
        "cushing",
        "syndrome",
        "also",
        "hold",
        "composition",
        "matter",
        "patent",
        "covering",
        "selective",
        "cortisol",
        "modulators",
        "contact",
        "charles",
        "robb",
        "chief",
        "financial",
        "officer",
        "corcept",
        "therapeutic",
        "crobb",
        "source",
        "corcept",
        "therapeutic",
        "incorporated"
    ]
}